How Long Should You Stay on HRT?

There is no fixed time limit on how long you should stay on HRT.

That’s the honest, slightly anticlimactic answer — and it’s backed by the major menopause guidance bodies, from The Menopause Society to ACOG. You stay on hormone therapy for as long as the benefits outweigh the risks for you, reviewed with a clinician (usually once a year). Many women use it for a few years. Plenty use it far longer. A smaller group uses local vaginal estrogen more or less indefinitely.

Here’s the part most pages haven’t caught up to yet: in 2025 the FDA removed the old boxed-warning instruction to take menopausal hormone therapy at the lowest dose for the shortest time, and it approved the first updated labels in February 2026. [1][2] The blanket “stop at five years, off by 60” rule that so many women were handed isn’t supported by current guidance.

So if no number applies to everyone, what doesdecide your answer? Five things: your formulation (estrogen-only vs. combined, patch vs. pill, systemic vs. vaginal), why you started, your age, how long it’s been since menopause, and your personal and family health history. We’ll walk through each one, show you the one real catch nobody should hide from you, and give you a plain decision framework plus a checklist to take to your next appointment.

HRT duration at a glance

A quick map — the full, sourced breakdown is further down. Last verified June 15, 2026.

Is there a time limit on HRT?

No — there is no maximum number of years or cut-off age that applies to everyone.The major guidance bodies have all moved from a number to a conversation: stay on HRT as long as the benefits outweigh the risks for you, and review it regularly. The Menopause Society says hormone therapy doesn’t need to be stopped just because you turn 60 or 65. [3]

For about twenty years, the rule sounded simple: lowest dose, shortest time, stop by five years. That rule didn’t survive the evidence. As far back as 2017, the group now called The Menopause Society reviewed the research and concluded that “lowest dose, shortest duration” advice could be inadequate, or even harmful, for some women — because it pushed people off treatment that was still helping them. [4]

We pulled together what each major US and UK guidance body actually says right now, because no single page lays them side by side.

The pattern jumps out: every one of these bodies traded the deadline for a decision.“How long” is no longer a year. It’s a question of whether the treatment is still right for you. As ACOG’s president put it after the 2025 label change, the goal is to put shared decision-making back where it belongs — between patients and their own clinicians. [8]

Why you were told to stop at 5 years — and what changed in 2026

The five-year fear traces back to a 2002 study that scared everyone — and to FDA label language that has now been removed.The original alarm was applied too broadly: it came from women who were, on average, much older than the women who start HRT for symptoms. In 2025 the FDA pulled its strongest warnings off estrogen products and dropped the “lowest dose, shortest time” instruction, and the first updated labels were approved in February 2026. [1][2]

The fear didn’t come from nowhere. In 2002, a large trial called the Women’s Health Initiative (WHI) reported higher risks with combined estrogen-plus-progestin therapy, and prescriptions fell off a cliff almost overnight. What got lost in the panic: the WHI enrolled postmenopausal women aged 50 to 79, with an average age around 63, while many women who start HRT for hot flashes and night sweats are closer to 45 to 55. [1] So the trial mostly measured what happens when you start hormones late in life — not what happens when you treat a 51-year-old with brutal symptoms.

Two decades of newer research reshaped the picture, and in 2025 the regulators caught up. After convening an expert panel in July 2025, the FDA announced in November that it would remove the “boxed” warnings — its strongest, scariest label format — and the long-standing instruction to use the lowest dose for the shortest time. On February 12, 2026, it approved updated labeling for the first six products (Prometrium, Divigel, Cenestin, Enjuvia, Estring, and Bijuva); Reuters reported that 29 drug manufacturers had submitted updated labels. [1][2]

Here’s exactly what moved and what didn’t — the part most coverage blurs.

Source: FDA labeling-change materials, 2025–2026. [1][2]

A couple of things worth holding onto. First, “lowest effective dose” still makes sense as a general prescribing idea — NICE and others still advise using the dose that controls your symptoms, not more. What changed is the “shortest duration” mandate, which is gone. Second, the updated labels also reflect newer thinking about timing: they add consideration of starting hormone therapy for moderate-to-severe hot flashes and night sweats in women under 60 or within 10 years of menopause. [1]

And here’s a number that says a lot about how undertreated this is: the FDA noted that in 2020 there were about 41 million U.S. women aged 45–64, but only around 2 million women aged 46–65 had a prescription for systemic estrogen-alone or estrogen-plus-progestogen therapy. [1]

Want the full history of the label change? See our explainer on the FDA black box warning for HRT.

What actually changes the longer you take HRT

Most of the benefits hold while you’re taking it. The risks that can grow with time depend heavily on your formulation and how it’s delivered — not just on the number of years.Symptom relief lasts as long as the treatment is working, and HRT’s protection against bone fractures is maintained while you’re on it but fades once you stop. [6] On the risk side, the most-discussed duration-related risk is breast cancer with combined HRT — but it isn’t the only thing that can scale.

Three risks can rise with dose or length of use, and they’re not the same for everyone:

• Breast cancer, mainly with combined HRT (estrogen plus a progestogen), rises with duration of use. [6]
• Stroke and blood clots are more linked to oral estrogen (pills) and to higher doses; through-the-skin estrogen looks lower-risk on this front. [9]
• Endometrial (uterine) cancer rises with estrogen that isn’t properly balanced by a progestogen, and the risk grows the longer estrogen-only therapy is used. [10]

The one most people came here worried about, stated straight:

If you have a uterus and take combined HRT, there’s a small increase in breast-cancer risk that grows the longer you use it. That’s the honest basis for the old five-year worry, and we’re not going to bury it. But “small” matters here. A 2020 study of UK medical records estimated roughly 9 to 36 extra breast-cancer cases per 10,000 women each year among combined HRT users, and about 3 to 8 extra per 10,000 per year for estrogen-only users. [11] Real, but modest — and bigger the longer you use it.

A few things the scary version usually leaves out:

• It’s not only a “10-year” problem, and it’s not all formulations. A large 2019 analysis pooling 24 studies found breast-cancer risk rose steadily with longer use and was higher for combined therapy than for estrogen-only — with vaginal estrogen the exception (no increased risk). Some increase remained even after stopping. [12]
• The progestogen type may matter — but don’t treat it as a loophole. Observational studies (and the British Menopause Society) suggest combinations using micronized progesterone may carry a lower breast-cancer signal than older synthetic progestins, with the most reassuring data covering use up to about five years. But NICE’s 2024 review judged the evidence insufficient to confirm that micronized progesterone is truly lower-risk. It’s a reasonable thing to ask your clinician about — not a “safe forever” pass. [6][13]
• Estrogen-only behaves differently. For women with a prior hysterectomy who take estrogen by itself, the WHI estrogen-alone arm found a more favorable breast-cancer pattern than the combined arm. Don’t stretch that finding to every personal history, but it’s why estrogen-only is generally the lower-risk side of this conversation. [14]
• One fact worth keeping. Research has not shown that HRT increases the risk of dying from breast cancer. [13]

So the drawback is real, but it’s specific, not universal — which is exactly why a one-size deadline never made sense. Here it is laid out by formulation.

One more variable hides inside “formulation”: route. Estrogen taken through the skin (a patch or gel) appears to carry a lower stroke and clot risk than estrogen swallowed as a pill. [9] If duration is your worry, the delivery method is worth raising with your clinician — not just the number of years.

As Dr. JoAnn Manson, a lead investigator on the WHI, summed it up after the 2025 label change: no one has to be off hormones by a predetermined age, but for combinationtherapy it’s reasonable to start thinking about whether to continue within about five to seven years, because of that rising breast-cancer risk. [15] Two true things at once. That’s the whole game.

How long should you stay on HRT? Start with your situation

The honest answer is “as long as it’s doing more good than harm for you specifically” — so the useful move is to find your situation. A woman using vaginal estrogen for dryness, a woman with early menopause, a woman starting systemic HRT at 62, and a woman with unexplained bleeding are not making the same decision. Below is a plain map.

The HRT Index Duration Decision Matrix

Assembled from FDA, The Menopause Society, ACOG, NICE, NHS, and USPSTF guidance. Last verified June 15, 2026.

When should you keep taking HRT, taper, or stop?

Continuing makes sense when symptoms still affect your life, or when there’s another clear reason like early menopause. Tapering or stopping makes sense when your symptoms have settled, side effects outweigh the benefit, your health changes, or you simply prefer to. The one thing that is not, on its own, a good reason to stop: hitting an arbitrary age or year count.

Good reasons to keep going

• Your hot flashes, night sweats, or sleep disruption are still there without HRT, and they’re affecting your life. Hormone therapy remains the most effective treatment for these symptoms. [6]
• You had early menopause or premature ovarian insufficiency, where therapy is generally continued at least to the usual menopause age for bone and heart protection. [6]
• Your vaginal or urinary symptoms persist — these rarely fade on their own, and local estrogen can keep handling them. [6]

Good reasons to taper or stop

• Your symptoms have been quiet for a while and you’d like to find out if you still need treatment.
• Side effects outweigh the benefit, and adjusting your dose, formulation, or route hasn’t fixed it.
• Your health history changed (more on red flags below).
• You’d simply rather not continue. Personal preference is a complete reason. You don’t owe anyone a clinical justification.

Reasons that aren’t enough by themselves

• “I’ve hit five years.” Five years isn’t a safety cliff — it was a rule of thumb the evidence, and now the FDA’s boxed warning, moved past. [1]
• “I turned 60.” Age alone isn’t a stop signal; the guidance says so directly. [5]
• “I should take a break.” There’s no proven benefit to routine breaks, and stopping just to pause can bring symptoms back without lowering long-term risk.

One reason that deserves its own line: “anti-aging” or disease prevention

If your main reason to stay on HRT is to prevent heart disease or dementia, or to feel younger, the evidence doesn’t support that goal. The U.S. Preventive Services Task Force gives its strongest “don’t” rating (a D grade) to using systemic hormone therapy for the primary prevention of chronic conditions in postmenopausal women. [19] Important nuance: that recommendation is about prevention in women without symptoms — it does notapply to using HRT to treat hot flashes or vaginal symptoms, and it doesn’t apply to early or surgical menopause. [19]

Red flags — talk to a clinician before changing anything

The FDA lists situations to discuss before using (or continuing) menopausal hormone therapy, including unexplained vaginal bleeding, certain cancers, a prior stroke or heart attack, blood clots, and liver disease. [20] NICE advises stopping systemic HRT if you’re diagnosed with breast cancer. [6] If any of these apply, don’t start, stop, or adjust on your own.

Do you have to wean off HRT, or can you stop cold turkey?

You don’t have to taper, but many clinicians suggest it. UK guidance from NICE offers a choice: gradually reducing your dose may ease the return of symptoms in the short term, while gradually reducing and stopping outright make no difference to symptoms in the longer run. [6] Either way, plan it with a clinician rather than quitting on your own.

What’s clear in practice is that stopping suddenly often feels worse, because symptoms can come back fast and all at once — so the NHS says gradually reducing your dose, often over a few months, is usually recommended over stopping abruptly. [7]

A few practical things worth knowing before you taper:

• Timing can be strategic. If you’d struggle with returning symptoms right now — a brutal stretch at work, a big event, sleep already shot — it’s fine to wait for a calmer window.
• Vaginal symptoms are the exception. Even women who taper off systemic HRT often still need local vaginal estrogen, because dryness and urinary changes don’t fade the way hot flashes do. [7]
• Restarting is a normal option. If symptoms come roaring back and the benefits still outweigh the risks for you, restarting is a perfectly normal thing to discuss with your clinician. [6][7]
• Don’t DIY a taper schedule. Cutting, skipping, or splitting doses on your own can backfire. Ask whether your specific product can be stepped down safely first.

What happens when you stop HRT?

When you stop, menopause symptoms can return as your hormone levels fall — hot flashes, poor sleep, and vaginal dryness are the ones people notice most. For some women symptoms stay gone; for others they come back and settle over a few months. About half of women have hot flashes return after stopping, regardless of how old they are or how long they were on it. [18]

The frustrating truth: there’s no way to know in advance which group you’ll be in, because while you’re on HRT it’s masking whether your body has moved past the worst of menopause. The only real test is a trial off treatment, ideally a gradual one.

Two longer-term things shift when systemic estrogen stops:

• Bone protection tapers off. Estrogen’s protection against fractures is maintained while you’re on HRT but decreases once you stop. [6] Worth a specific conversation if bone health was part of why you started.
• Weight is mostly not affected. Despite the common fear, current evidence doesn’t show stopping HRT causes meaningful weight change — a 2023 systematic review found hormone therapy unlikely to cause significant weight changes during or after menopause. [25]

A simple 90-day “should I restart?” tracker

If you’re coming off HRT, track these for three months. It turns a guessing game into data — and the NHS says to see a clinician if symptoms persist for several months after stopping. [7] Screenshot it for your phone:

Can you stay on HRT after 60 or 65?

Yes, for many women — and there’s a critical difference between starting late and continuing something that’s working. ACOG recommends against routinely stopping systemic estrogen at age 65, because some women still need it for hot flashes. [5] Whether long-term use is right for you comes down to the same yearly benefit-versus-risk check, not your birthday.

This is the distinction most pages blur:

• Starting systemic HRT for the first time after 60 — or more than 10 years past menopause — comes with a less favorable balance, and it deserves a careful, individual review (often a lower dose, often a patch). [3][9]
• Continuing therapy you started near menopause and that’s still working is a different situation. Age, by itself, is not a reason to stop.

Can you take HRT for the rest of your life?

Some women do use HRT long-term — but “forever” is the wrong way to frame it.Continue only while there’s a clear reason, the benefits still outweigh the risks, and the plan is reviewed periodically. NICE notes that HRT is unlikely to affect life expectancy. [6]

“For life” sounds dramatic, but in practice it just means “for as long as the yearly review keeps coming back in favor.” Women who started near menopause, who have stubborn symptoms, who take estrogen-only, or who had early menopause often stay on well into later years. What lifelong use is not is a refill you drift into without anyone re-checking — especially on combined therapy, where the duration-related breast-cancer risk is real.

For local vaginal estrogen, the bar is lower still. Because only a tiny amount is absorbed and serious adverse effects are very rare, it’s routinely used long-term as needed — which is exactly why the FDA condensed its warnings for those low-dose products in 2025. [6][1]

Estrogen-only vs. combined vs. vaginal — and a word on compounded

Your HRT type changes the duration math.If you have a uterus and take systemic estrogen, you usually need a progestogen to protect your uterine lining. If you’ve had a hysterectomy, estrogen alone may be fine. And local vaginal estrogen is a different, lower-risk conversation from whole-body therapy. [16][6]

A quick definition first: systemic HRT travels through your whole body (pills, patches, gels) and treats body-wide symptoms like hot flashes. Local (vaginal) estrogen works mostly right where you put it, with only a tiny amount reaching the bloodstream.

If you have a uterus:taking estrogen without a progestogen raises the risk of endometrial cancer, and that risk grows the longer unbalanced estrogen is used. Adding a progestogen lowers it — that’s why combined therapy exists. [16][10] NICE recommends combined HRT for people with a uterus, and estrogen-only after a total hysterectomy. [6]

On compounded “bioidentical” hormones, we’ll be blunt because it matters: compounded products should not be treated as safer for long-term use just because they’re marketed as “natural” or “bioidentical.” The FDA says compounded drugs are not FDA-approved, and the agency does not verify their safety, effectiveness, or quality before they’re sold. ACOG continues to recommend against compounded estrogen products. [8][21] If long-term safety is on your mind, that’s a strong reason to ask your clinician about an FDA-approved option. See our full bioidentical vs. compounded HRT comparison.

Is an online menopause provider the right next step for you?

Sometimes — and sometimes you need an in-person exam or a specialist instead.Online menopause care can be a good fit for routine symptom reviews, questions about FDA-approved options, dose or route changes, vaginal symptoms, or a second opinion when your current doctor is still using the old “stop at five years” rule.

That second-opinion point is a natural next step for some readers. If you were told to come off HRT just because of the calendar, that advice reflects an older standard — one the FDA’s own 2025 label change moved past. Given how few eligible women actually get this care — roughly 2 million of 41 million in 2020 — a lot of people simply never had the conversation. [1]

A few provider notes, kept factual rather than promotional. These are provider-stated facts, last checked June 15, 2026 — verify current details at the source before you rely on them.

Disclosure: The HRT Index may earn a commission if you use some provider links. Our medical and regulatory conclusions come from the sources listed below, not from any affiliate payment.

The HRT Index is an independent comparison resource for HRT telehealth providers. We don’t think “how long should I stay on HRT” is a question you answer by signing up for anything — it’s a question for you and a clinician. We mention telehealth only because, for many readers, finding a menopause-literate provider is the actual next step.

What to ask at your next HRT review

Your annual HRT review shouldn’t be a rushed refill.It should confirm why you’re still on it, whether your symptoms still justify it, whether your dose and route still fit, and whether anything in your health has changed. Bring questions, not just your prescription.

Here’s the checklist we’d take in ourselves. Screenshot it for your phone:

A quick note on testosterone (TRT) and gender-affirming HRT

This guide is about menopausal hormone therapy. If you’re asking about testosterone therapy or gender-affirming hormone therapy, the duration logic is different — use resources built for those treatments and a clinician who manages them.

• Testosterone therapy. In the U.S., testosterone is a Schedule III controlled substance. It requires a prescription and ongoing medical supervision, and the duration considerations differ from estrogen-based menopause HRT. See our guide to blood tests and hormone monitoring for details.
• Gender-affirming hormone therapy. This is typically long-term, ongoing care, managed by clinicians experienced in that area. The “stop at five years” framing in this article doesn’t apply.

Frequently asked questions

Still not sure which HRT program is right for you?

You came here for a number and found something better: a way to make the decision yourself, with your clinician, on current evidence instead of a twenty-year-old myth. If you’d like that decision turned into a personal plan —